Sustained Efficacy and Safety in C3 Glomerulopathy Following 36 Months of Oral Treatment with Iptacopan: Interim Participant Results from the APPEAR-C3G Extension Study (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-OR078; Pres time: Oct 24, 2026; 05:30 PM - 05:42 PM; Location: Four Seasons Ballroom 2, Convention Center; P3 | "Conclusion This analysis confirms previous findings demonstrating sustained efficacy and safety of oral iptacopan over 3 years. To date, this is the largest cohort with long-term follow up data in participants with C3G receiving iptacopan in clinical trials, addressing a gap that may inform clinical practice in this population."
Clinical • Late-breaking abstract • Complement-mediated Rare Disorders • Glomerulonephritis • Infectious Disease • Meningococcal Infections
|
|
Carla M. Nester; Richard J. Smith; David Kavanagh; Marina Vivarelli; Giuseppe Remuzzi; Minghui Zhao; Edwin Kwan Soon Wong; Shiwei Cao; Rubeen K. Israni; Raquel Luna Yolba; Severina Jacinto-Sanders; Jean Grisouard; Andrew S. Bomback
|